

## ASX ANNOUNCEMENT

### Quarterly Cashflow Report

**29th January 2016:** Brisbane, Australia - Analytica Ltd (ASX: ALT) manufacturer of the PeriCoach® System, today released its Appendix 4C – Quarterly Cashflow report for the quarter ended 31<sup>st</sup> December 2015.

Receipts from sales of PeriCoach in Analytica's key markets of Australia, the UK and the US totalled \$47,000 while marketing and sales expenditure for the quarter totalled \$714,000. During the quarter, Analytica developed distribution agreements with partners in the UK. One of these partners is the number one supplier of pelvic health devices to consumers in that market. By the June quarter 2016, Analytica also expects to have identified and completed distribution agreements with a number of distribution partners in the Australian market. These agreements could be important in assisting the growth of PeriCoach sales in the future as the company seeks to partner PeriCoach with a major multinational corporation.

R&D expenditure was \$424,000 for the quarter. The release of PeriCoach in the USA, UK and Australia provided Analytica with an important opportunity to engage with specialist pelvic floor clinicians in those countries. These relationships combined with the deep experience of the company's clinical advisory boards has enabled Analytica to publish papers and testimonials and importantly, it has assisted in the ongoing development of PeriCoach. The company has continued to exhibit PeriCoach at major international urology and gynecology conferences and continues to receive very positive feedback

Analysis of the significant amount of data being collected from PeriCoach users is providing valuable feedback for the development of next generation of PeriCoach. Through sales of PeriCoach, Analytica is building the world's largest database on the pelvic floor muscle exercise and development of future generations of PeriCoach will ensure more detailed and extensive data becomes available. In order to stay at the forefront of treating stress urinary incontinence, Analytica will make a significant investment in the development of analytical tools to utilise this data, providing superior treatment options for health providers.

Continuing to develop PeriCoach will not only extend the company's leadership but may also open additional higher-value markets and increase the opportunity to partner with multinational medical device companies.

Analytica will continue to concentrate on specific market segments while focussing on the further development of the PeriCoach.

During the quarter, Analytica also made solid progress with its post-approval clinical trial, which will provide independent data and further evidence of PeriCoach's value. Three additional trial sites were added with additional patients being enrolled.

The cash balance as at 31<sup>st</sup> December was -\$6,000 which was assisted by a loan from the Chairman of \$277,000, from the previously announced \$400,000 loan facility. However, this cash balance did not include the benefit of the R&D tax incentive of \$1.901 million received after quarter end on 18<sup>th</sup> January. As at 27 January 2016, Analytica's cash balance was \$1.197 million.

Analytica CEO Geoff Daly said: "The quarter has been another period of progress for Analytica as we continue with our goal to establish PeriCoach as the leading device for pelvic floor muscle training and the treatment of urinary incontinence. A focus on R&D and finding sales partners for PeriCoach are critical parts of our strategy and we made good progress in both these areas during the quarter."



Analytica's investment in R & D will require further capital in the coming period. As a result of engagement with Australian and Asian investment institutions a number of capital raising initiatives are being considered by the board.

For more information please contact [InvestorRelations@analyticamedical.com](mailto:InvestorRelations@analyticamedical.com)

For more information about the PeriCoach System, visit: [www.PeriCoach.com](http://www.PeriCoach.com)

For more information about Analytica, visit [www.AnalyticaMedical.com](http://www.AnalyticaMedical.com)

Follow us on:



#### **About Analytica Limited**

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.

PeriCoach has regulatory clearance in Australia, and has CE mark has and USFDA 510(k) clearance. The product has been on sale in Australia and New Zealand since January, and recently launched in the UK and Ireland, and in the USA. The US market for incontinence pads is \$5 billion pa. It is projected that by 2030, 5.6 million women in Australia will suffer urinary incontinence.



# Appendix 4C

## Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

Analytica Limited

ABN

12 006 464 866

Quarter ended ("current quarter")

31/12/2015

### Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date (6 months) \$A'000
1.1 Receipts from customers	47	131
1.2 Payments for		
(a) staff costs	(331)	(692)
(b) advertising and marketing	(714)	(1,492)
(c) research and development	(424)	(714)
(d) leased assets	-	-
(e) other working capital	(369)	(569)
(f) realised currency gains	(12)	(35)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	3	7
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Other-		
(a) Net sales income	-	-
(b) R & D Tax Concession	-	-
(c) Royalty Income	-	-
(d) Other Grant Income	-	-
<b>Net operating cash flows</b>	<b>(1,800)</b>	<b>(3,364)</b>

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

		Current quarter \$A'000	Year to date (6 months) \$A'000
1.8	Net operating cash flows (carried forward)	<b>(1,800)</b>	<b>(3,364)</b>
<b>Cash flows related to investing activities</b>			
1.9	Payment for acquisition of:		
	(a) businesses	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-7	-7
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other (purchase of Convertible Notes )	-	-
	<b>Net investing cash flows</b>	<b>-7</b>	<b>-7</b>
<b>1.14</b>	<b>Total operating and investing cash flows</b>	<b>1,807</b>	<b>3,371</b>
<b>Cash flows related to financing activities</b>			
1.15	Proceeds from issues of shares	-	2,867
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	277	277
1.18	Repayment of borrowings:	-	-
1.19	Dividends paid	-	-
1.20	Other Creditors (costs of fund raising)	(8)	(333)
	<b>Net financing cash flows</b>	<b>269</b>	<b>2,811</b>
	<b>Net increase (decrease) in cash held</b>	<b>1,538</b>	<b>560</b>
1.21	Cash at beginning of quarter/year to date	1,532	554
1.22	Exchange rate adjustments to item 1.20	-	-
1.23	<b>Cash at end of quarter</b>	<b>* -6</b>	<b>-6</b>

\* R&D Tax incentive payment of \$1,901 was received on the 18<sup>th</sup> January 2016

+ See chapter 19 for defined terms.

**Payments to directors of the entity and associates of the directors**

**Payments to related entities of the entity and associates of the related entities**

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	54
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

Payment of director's fees and compulsory superannuation.
---

**Non-cash financing and investing activities**

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A
-----

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A
-----

**Financing facilities available**

*Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).*

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	400	277
3.2	Credit standby arrangements	-	-

---

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

**Reconciliation of cash**

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	-6	1,532
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	-
4.4 Other (provide details)	-	-
<b>Total: cash at end of quarter</b> (item 1.23)	-6	1,552

**Acquisitions and disposals of business entities**

	Acquisitions	Disposals
5.1 Name of entity	N/A	N/A
5.2 Place of incorporation or registration		
5.3 Consideration for acquisition or disposal		
5.4 Total net assets		
5.5 Nature of business		

**Compliance statement**

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here:

Date:

Print name:

---

+ See chapter 19 for defined terms.